NWPH.F Stock Overview
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Newron Pharmaceuticals S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF8.52 |
| 52 Week High | CHF8.55 |
| 52 Week Low | CHF5.22 |
| Beta | 0.70 |
| 1 Month Change | 0% |
| 3 Month Change | -0.35% |
| 1 Year Change | n/a |
| 3 Year Change | 204.29% |
| 5 Year Change | -7.89% |
| Change since IPO | -65.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| NWPH.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.08% | 1.2% |
| 1Y | n/a | 13.2% | 24.9% |
Return vs Industry: Insufficient data to determine how NWPH.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how NWPH.F performed against the US Market.
Price Volatility
| NWPH.F volatility | |
|---|---|
| NWPH.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NWPH.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NWPH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 22 | Stefan Weber | www.newron.com |
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company’s product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication.
Newron Pharmaceuticals S.p.A. Fundamentals Summary
| NWPH.F fundamental statistics | |
|---|---|
| Market cap | US$151.45m |
| Earnings (TTM) | -US$17.22m |
| Revenue (TTM) | US$9.61m |
15.8x
P/S Ratio-8.8x
P/E RatioIs NWPH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NWPH.F income statement (TTM) | |
|---|---|
| Revenue | €9.06m |
| Cost of Revenue | €0 |
| Gross Profit | €9.06m |
| Other Expenses | €25.28m |
| Earnings | -€16.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 19, 2024
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 100.00% |
| Net Profit Margin | -179.13% |
| Debt/Equity Ratio | -160.6% |
How did NWPH.F perform over the long term?
See historical performance and comparison